Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IPH5201 · 1 trial · 1 indication
The primary endpoint is safety as assessed by the presence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs).
Number of subjects with clinically significant laboratory values from baseline including blood counts, liver, kidney and pancreas tests, electrolytes, and blood clotting.
12 lead ECGs will be measured to identify clinical significant abnormalities including ECGs that demonstrate a QTcF value \>500ms, 2 additional 12-lead ECGs should be obtained over a 30 minute time period to confirm prolongation based on the average QTcF value
| Arm | Type | Description |
|---|---|---|
| IPH5201 monotherapy dose escalation | EXPERIMENTAL | IPH5201 monotherapy |
| IPH5201 dose escalation with durvalumab | EXPERIMENTAL | IPH5201 plus durvalumab |
| IPH5201 dose escalation with durvalumab + oleclumab | EXPERIMENTAL | IPH5201 plus durvalumab and oleclumab |
| Name | Type | Description |
|---|---|---|
| IPH5201 | BIOLOGICAL | Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years |
| durvalumab | BIOLOGICAL | Durvalumab Q3W for a maximum of 2 years |
| oleclumab | BIOLOGICAL | Oleclumab Q3W for a maximum of 2 years |
Inclusion Criteria: * Adult subjects; age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Subjects diagnosed with advanced solid tumors. * For Part 1 and Part 2 (IPH5201 in monotherapy or combined with durvalumab):Subjects must be refractory to standard therap...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
IPH5201 is an investigational monoclonal antibody being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated as a potential therapy for patients with advanced solid tumors.
IPH5201 is a monoclonal antibody, but its specific molecular target has not been disclosed in the available information. The drug is being investigated for its potential role in treating advanced solid tumors, though the exact mechanism of action has not been detailed.
IPH5201 is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced solid tumors.
IPH5201 is currently in Phase 1 clinical development. It is an investigational drug and has not received approval from regulatory authorities. The Phase 1 trial has been completed, and the drug remains in the early stages of clinical investigation for advanced solid tumors.
IPH5201 has been studied in one clinical trial with the identifier NCT04261075. This Phase 1 trial evaluated IPH5201 as a monotherapy or in combination with durvalumab, with or without oleclumab, in subjects with advanced solid tumors. The trial enrolled 57 participants and has been completed.
No, IPH5201 is a distinct investigational drug. Durvalumab and oleclumab are separate agents that were used in combination with IPH5201 in a clinical trial. IPH5201 was studied both as a monotherapy and in combination with these other drugs, but it is not the same as either of them.